Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Whales with a lot of money to spend have taken a noticeably bearish stance on Sarepta Therapeutics.
Looking at options history for Sarepta Therapeutics (NASDAQ:SRPT) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $374,000 and 9, calls, for a total amount of $1,862,920.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $155.0 to $180.0 for Sarepta Therapeutics over the last 3 months.
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Sarepta Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Sarepta Therapeutics's substantial trades, within a strike price spectrum from $155.0 to $180.0 over the preceding 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
SRPT | CALL | TRADE | BULLISH | 08/16/24 | $4.5 | $2.0 | $3.6 | $175.00 | $1.4M | 6.1K | 974 |
SRPT | PUT | TRADE | NEUTRAL | 01/16/26 | $26.2 | $22.3 | $24.2 | $155.00 | $121.0K | 0 | 50 |
SRPT | CALL | TRADE | BULLISH | 07/19/24 | $0.55 | $0.2 | $0.55 | $180.00 | $91.3K | 2.3K | 347 |
SRPT | CALL | SWEEP | BULLISH | 08/16/24 | $3.2 | $3.1 | $3.1 | $175.00 | $83.3K | 6.1K | 271 |
SRPT | PUT | SWEEP | BEARISH | 07/19/24 | $18.0 | $16.1 | $18.0 | $170.00 | $72.0K | 69 | 0 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Having examined the options trading patterns of Sarepta Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $191.6.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, Benzinga Pro gives you real-time options trades alerts.
Posted In: SRPT